Skip to main content

Advertisement

SpringerLink
Log in

Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans

  • Molecular Toxicology
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Abstract

Several members of the ATP binding cassette (ABC) transporter protein superfamily perform xenobiotic efflux functions in mammals, limiting gut absorption, mediating excretion, and controlling entry of a wide range of chemicals to sensitive compartments such as brain, testes and foetus. Perhaps the best characterised of these is p-glycoprotein (gene name ABCB1/MDR1), a barrier epithelia expressed protein with structurally diverse substrates, including the avermectin pesticides. In specific mouse and dog strains, ABCB1 mutations have been identified that result in loss of p-glycoprotein function in the blood brain barrier (BBB) and increased susceptibility to avermectin neurotoxicity. As yet no large rearrangements of the human ABCB1 gene analogous to those in the mouse and dog have been identified. However, numerous human ABCB1 single nucleotide polymorphisms (SNPs) have been identified, the allelic frequencies of which vary with ethnicity. There is no clear consensus on whether or not SNPs, or combinations of SNPs, reduce human p-glycoprotein functionality. However, recent in vivo human data indicate that the two commonest ABCB1 haplotypes both exhibit full BBB functionality. We discuss here the role of p-glycoprotein in limiting brain absorption of avermectin pesticides, as well as the potential impact of the reported functional effects and population frequencies of known ABCB1 polymorphisms on avermectin pesticide risk assessments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Aarnoudse AL, van Schaik RH, Dieleman J, Molokhia M, van Riemsdijk MM, Ligthelm RJ, Overbosch D, van der Heiden IP, Stricker BH (2006) MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 80:367–374

    Article  PubMed  CAS  Google Scholar 

  • Allabi AC, Horsmans Y, Issaoui B, Gala JL (2005) Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 61:97–102

    Article  PubMed  CAS  Google Scholar 

  • Bain LJ, LeBlanc GA (1996) Interaction of structurally diverse pesticides with the human mdr1 gene product P-glycoprotein. Toxicol Appl Pharmacol 141:288–298

    PubMed  CAS  Google Scholar 

  • Bauer B, Hartz Am, Fricker G, Miller Ds (2004) Pregnane X receptor upregulation of P-glycoprotein expression and. Mol Pharmacol 66:413–419

    PubMed  CAS  Google Scholar 

  • Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537–592

    Article  PubMed  CAS  Google Scholar 

  • Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Muller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, Muller M (2005) Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 78:182–190

    Article  PubMed  CAS  Google Scholar 

  • Ceckova-Novotna M, Pavek P, Staud F (2006) P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 22(3):400–410

    Article  PubMed  CAS  Google Scholar 

  • Chowbay B, Li H, David M, Cheung YB, Lee EJ (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60:159–171

    Article  PubMed  CAS  Google Scholar 

  • Chung K, Yang CC, Wu ML, Deng JF, Tsai WJ (1999) Agricultural avermectins: an uncommon but potentially fatal cause of pesticide poisoning. Ann Emerg Med 34:51–57

    Article  PubMed  CAS  Google Scholar 

  • Crivori P, Reinach B, Pezzetta D, Poggesi I (2006) Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharm 3:33–44

    Article  PubMed  CAS  Google Scholar 

  • Frelet A, Klein M (2006) Insight in eukaryotic ABC transporter function by mutation analysis. FEBS Lett 580:1064–1084

    Article  PubMed  CAS  Google Scholar 

  • Geary TG (2005) Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol 21:530–532

    Article  PubMed  CAS  Google Scholar 

  • Hitzl M, Schaeffeler E, Hocher B, Slowinski T, Halle H, Eichelbaum M, Kaufmann P, Fritz P, Fromm MF, Schwab M (2004) Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 14:309–318

    Article  PubMed  CAS  Google Scholar 

  • Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J (2006) ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 15:797–805

    Article  PubMed  CAS  Google Scholar 

  • Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478

    Article  PubMed  CAS  Google Scholar 

  • Huang J, Casida JE (1997) Avermectin B1a binds to high- and low-affinity sites with dual effects on the gamma-aminobutyric acid-gated chloride channel of cultured cerebellar granule neurons. J Pharmacol Exp Ther 281:261–266

    PubMed  CAS  Google Scholar 

  • Ishikawa T, Onishi Y, Hirano H, Oosumi K, Nagakura M, Tarui S (2004) Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol Pharm Bull 27:939–948

    Article  PubMed  CAS  Google Scholar 

  • Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162

    Article  PubMed  CAS  Google Scholar 

  • Kerb R (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234:4–33

    Article  PubMed  CAS  Google Scholar 

  • Kim RB (2002) Transporters and xenobiotic disposition. Toxicology 181–182:291–297

    Article  PubMed  Google Scholar 

  • Kim DW, Kim M, Lee SK, Kang R, Lee SY (2006) Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrugresistant epilepsy. Seizure 15:344–347

    Article  PubMed  Google Scholar 

  • Kimchi-Sarfaty C, Gribar JJ, Gottesman MM (2002) Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 62:1–6

    Article  PubMed  CAS  Google Scholar 

  • Krieger RI, Rosenheck LA, Schuester LL (1997) Adult and infant abamectin exposures following Avert 310 and pressurized gel crack and crevice treatment. Bull Environ Contam Toxicol 58:681–687

    Article  PubMed  CAS  Google Scholar 

  • Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481–494

    Article  PubMed  CAS  Google Scholar 

  • Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA, Ly VT, Strauss JR, Wang RW, Wang Z, Pippert TR, Umbenhauer DR (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27:581–587

    PubMed  CAS  Google Scholar 

  • Lankas GR, Minsker DH, Robertson RT (1989) Effects of ivermectin on reproduction and neonatal toxicity in rats. Food Chem Toxicol 27:523–529

    Article  PubMed  CAS  Google Scholar 

  • Lankas GR, Cartwright ME, Umbenhauer D (1997) P-Glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 143:357–365

    Article  PubMed  CAS  Google Scholar 

  • Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12:457–463

    Article  PubMed  CAS  Google Scholar 

  • Lanning CL, Wehner TA, Norton JA, Dunbar DM, Grosso LS (1997) Correlation of actual strawberry harvester exposure with that predicted from abamectin dislodgeable foliar residues. J Agric Food Chem 46:2340–2345

    Article  Google Scholar 

  • Lecoeur S, Videmann B, Mazallon M (2006) Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein. M Toxicol Lett 161(3):200–209

    Article  CAS  Google Scholar 

  • Leschziner GD, Andrew T, Pirmohamed M, Johnson MR (2006a) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. Advanced online publication

  • Leschziner G, Zabaneh D, Pirmohamed M, Owen A, Rogers J, Coffey AJ, Balding DJ, Bentley DB, Johnson MR (2006b) Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics 16:439–450

    CAS  Google Scholar 

  • Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216–237

    Article  PubMed  CAS  Google Scholar 

  • Loo TW, Clarke DM (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206:173–185

    Article  PubMed  CAS  Google Scholar 

  • Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33

    Article  PubMed  CAS  Google Scholar 

  • Matsuoka Y, Okazaki M, Kitamura Y, Taniguchi T (1999) Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J Neurobiol 39:383–392

    Article  PubMed  CAS  Google Scholar 

  • Mealey KL, Bentjen SA, Gay JM, Cantor GH (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11:727–733

    Article  PubMed  CAS  Google Scholar 

  • Morita N, Yasumori T, Nakayama K (2003) Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65:1843–1852

    PubMed  CAS  Google Scholar 

  • Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K (2002) Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 25:1356–1359

    Article  PubMed  CAS  Google Scholar 

  • Mutoh K, Mitsuhashi J, Kimura Y, Tsukahara S, Ishikawa E, Sai K, Ozawa S, Sawada J, Ueda K, Katayama K, Sugimoto Y (2006) A T3587G germline mutation of the MDR1 gene encodes a nonfunctional P-glycoprotein. Mol Cancer Ther 5:877–884

    Article  PubMed  CAS  Google Scholar 

  • Oselin K, Mrozikiewicz PM, Gaikovitch E, Pahkla R, Roots I (2003) Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 59:347–350

    Article  PubMed  CAS  Google Scholar 

  • Pacque MC, Dukuly Z, Greene BM, Munoz B, Keyvan-Larijani E, Williams PN, Taylor HR (1989) Community-based treatment of onchocerciasis with ivermectin: acceptability and early adverse reactions. Bull World Health Organ 67:721–730

    PubMed  CAS  Google Scholar 

  • Pippert TR, Umbenhauer DR (2001) The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene. J Biochem Mol Toxicol 15:83–89

    Article  PubMed  CAS  Google Scholar 

  • Potocnik U, Ferkolj I, Glavac D, Dean M (2004) Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun 5:530–539

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez Novoa S, Barreiro P, Rendon A, Barrios A, Corral A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V (2006) Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C–>T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 42:291–295

    Article  PubMed  Google Scholar 

  • Sakaeda T (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20:391–414

    Article  PubMed  CAS  Google Scholar 

  • Schaefer M, Roots I, Gerloff T, (2006) In-vitro transport characteristics discriminate wild-type ABCB1(MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics 16:855–861

    PubMed  CAS  Google Scholar 

  • Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M (2001) Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383–384

    Article  PubMed  CAS  Google Scholar 

  • Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3–29

    Article  PubMed  CAS  Google Scholar 

  • Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP et al (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502

    Article  PubMed  CAS  Google Scholar 

  • Schumacher U, Mollgard K (1997) The multidrug-resistance P-glycoprotein (Pgp, MDR1) is an early marker of blood-brain barrier development in the microvessels of the developing human brain. Histochem Cell Biol 108:179–182

    Article  PubMed  CAS  Google Scholar 

  • Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S, van Veen HW (2006) New light on multidrug binding by an ATP-binding cassette transporter. Trends Pharmacol Sci 27(4):195–203

    Article  PubMed  CAS  Google Scholar 

  • Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348:1442–1448

    Article  PubMed  CAS  Google Scholar 

  • Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ (2005) Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46:643–647

    Article  PubMed  CAS  Google Scholar 

  • Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lotsch J (2003) Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13:651–660

    Article  PubMed  CAS  Google Scholar 

  • Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104(10):1441–1447

    PubMed  CAS  Google Scholar 

  • Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W (2006) Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27:602–609

    Article  PubMed  CAS  Google Scholar 

  • Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234

    Article  PubMed  CAS  Google Scholar 

  • Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, Ieiri I (2004) Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 311:1179–1187

    Article  PubMed  CAS  Google Scholar 

  • Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, Maeda J, Ikoma Y, Ito H, Suzuki K, Sugiyama Y (2006) Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med 47:1427–1433

    PubMed  CAS  Google Scholar 

  • Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic. J Pharmacol Exp Ther 297:1137–1143

    PubMed  CAS  Google Scholar 

  • Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738

    Article  PubMed  CAS  Google Scholar 

  • Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, Beare CM (1997) Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 146:88–94

    Article  PubMed  CAS  Google Scholar 

  • Urbatsch IL, Julien M, Carrier I, Rousseau ME, Cayrol R, Gros P (2000) Mutational analysis of conserved carboxylate residues in the nucleotide binding sites of P-glycoprotein. Biochemistry 39:14138–14149

    Article  PubMed  CAS  Google Scholar 

  • Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58:809–812

    PubMed  CAS  Google Scholar 

  • Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics 15:693–704

    Article  PubMed  CAS  Google Scholar 

  • Woodahl EL, Ho RJ (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5:11–19

    Article  PubMed  CAS  Google Scholar 

  • Xing Q, Gao R, Li H, Feng G, Xu M, Duan S, Meng J, Zhang A, Qin S, He L (2006) Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7(7):987–993

    Article  PubMed  CAS  Google Scholar 

  • Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG (2004) A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 76:418–427

    Article  PubMed  CAS  Google Scholar 

  • Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal-Bianco A, Zimprich A, Plumer S, Baumgartner C, Mannhalter C (2004) Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63:1087–1089

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, SK10 4TJ, UK

    Neil Macdonald & Alex Gledhill

Authors
  1. Neil Macdonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex Gledhill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil Macdonald.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Macdonald, N., Gledhill, A. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans. Arch Toxicol 81, 553–563 (2007). https://doi.org/10.1007/s00204-007-0193-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00204-007-0193-6

Keywords

Search

Navigation